Skip to main content

Advertisement

SpringerLink
Log in

Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer

  • LUNG CANCER
  • Published:
Lung Aims and scope Submit manuscript

Abstract

Purpose

Cancer-inflammation prognostic index (CIPI) is calculated by multiplying the concentration of carcinoembryonic antigen by neutrophil-to-lymphocyte ratio. CIPI has been reported as a prognostic factor for colorectal cancer. Although carcinoembryonic antigen and neutrophil-to-lymphocyte ratio have been reported as prognostic factors for non-small cell lung cancer (NSCLC), it has not been investigated whether CIPI is a useful marker.

Methods

We analyzed the prognostic factors, including CIPI, in 700 NSCLC patients treated by pulmonary resection. We also analyzed a subgroup of 482 patients with pathological stage I NSCLC.

Result

CIPI > 14.59 (P < 0.01), maximum standardized uptake value (SUVmax) > 5.35 (P < 0.01), lymphatic invasion (P = 0.01), and pathological stage (P < 0.01) were significant factors for relapse-free survival (RFS) in multivariate analysis. SUVmax > 5.35 (P < 0.01) and pathological stage (P < 0.01) were revealed as significant factors for overall survival in the multivariate analysis. In the subanalysis, CIPI > 14.88 (P = 0.01) and SUVmax > 5.07 (P < 0.01) were significant factors for RFS of pathological stage I NSCLC in multivariate analysis.

Conclusion

CIPI was a significant factor for RFS in NSCLC patients treated surgically, even in those with pathological stage I disease. SUVmax was also a significant factor for RFS and overall survival in NSCLC patients treated surgically, and for RFS in patients with pathological stage I NSCLC.

Trial Registration

The Institutional Review Board of Kanazawa Medical University approved the protocol of this retrospective study (Approval Number: I392), and written informed consent was obtained from all patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data Availability

The datasets generated and/or analyzed during the current study are not publicly available due to [our institutional restrictions e.g., them containing information that could compromise research participant privacy/consent], but are available from the corresponding author on reasonable request.

References

  1. Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48

    Article  PubMed  Google Scholar 

  2. Zahorec R (2001) Ratio of neutrophil to lymphocyte counts—rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 102:5–14

    CAS  PubMed  Google Scholar 

  3. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T (2011) Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res 31:2995–2998

    PubMed  Google Scholar 

  4. Forget P, Machiels JP, Coulie PG, Berliere M, Poncelet AJ, Tombal B et al (2013) Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol 3:650–660

    Article  Google Scholar 

  5. Shimizu K, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M (2015) Preoperative neutrophil/lymphocyte ratio and prognostic nutritional index predict survival in patients with non-small cell lung cancer. World J Surg Oncol 13:291

    Article  PubMed  PubMed Central  Google Scholar 

  6. Motono N, Mizoguchi T, Ishikawa M, Iwai S, Iijima Y, Hidetaka U (2022) Prognostic value of neutrophil-to-lymphocyte ratio and prognostic nutrition index in patients with non-small cell lung cancer receiving pulmonary resection. World J Surg Res 5:1401

    Google Scholar 

  7. Su YL, Tsai KL, Chiu TJ, Lin YM, Lee KC, Lu CC et al (2021) Development and validation of a novel serum prognostic marker for patients with metastatic colorectal cancer on regorafenib treatment. Cancers 13:5080

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. You JF, Hsu YJ, Chern YJ, Cheng CC, Jong BK, Liao CK et al (2022) Preoperative cancer inflammation prognostic index as a superior predictor of short- and long-term outcomes in patients with stage I-III colorectal cancer after curative surgery. Cancers 14:6232

    Article  PubMed  PubMed Central  Google Scholar 

  9. Grunnet M, Sorensen JB (2012) Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76:138–143

    Article  CAS  PubMed  Google Scholar 

  10. Brinkman GL, Coates EO (1963) The effect of bronchitis, smoking, and occupation on ventilation. Am Rev Respir Dis 87:684–693

    CAS  PubMed  Google Scholar 

  11. Li D, Yuan X, Liu J, Li C, Li W (2018) Prognostic value of prognostic nutritional index in lung cancer: a meta-analysis. J Thorac Dis 10:5298–5307

    Article  PubMed  PubMed Central  Google Scholar 

  12. Qiu C, Qu X, Shen X, Zheng C, Zhu L, Meng L et al (2015) Evaluation of prognostic nutritional index in patients undergoing radical surgery with nonsmall cell lung cancer. Nutr Cancer 67:741–747

    Article  PubMed  Google Scholar 

  13. Kim YS, Kim SJ, Kim TK, Kim IJ, Kim YD, Lee MK (2011) Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (Stage I and II) non-small cell lung cancer. Neoplasma 58:245–250

    Article  CAS  PubMed  Google Scholar 

  14. Nitadori J, Bograd AJ, Morales EA, Rizk NP, Dunphy MPS, Sima CS et al (2013) Preoperative consolidation-to-tumor ratio and SUVmax stratify the risk of recurrence in patients undergoing limited resection for lung adenocarcinoma ≤2cm. Ann Surg Oncol 20:4282–4288

    Article  PubMed  PubMed Central  Google Scholar 

  15. Motono N, Ueno M, Tanaka M, Machida Y, Usuda K, Sakuma T et al (2014) Differences in the prognostic significance of the SUVmax between patients with resected pulmonary adenocarcinoma and squamous cell carcinoma. Asian Pac J Cancer Prev 15:10171–10174

    Article  PubMed  Google Scholar 

  16. Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398:1344–1357

    Article  CAS  PubMed  Google Scholar 

  17. Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW et al (2021) Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLC. J Thorac Oncol 17:423–433

    Article  PubMed  Google Scholar 

  18. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H et al (2004) A randomized trial of adjuvant chemotherapy with uracil-tagafur for adenocarcinoma for the lung. N Engl J Med 350:1713–1721

    Article  CAS  PubMed  Google Scholar 

  19. Tsutani Y, Imai K, Ito H, Miyata Y, Ikeda N, Nakayama H et al (2022) Adjuvant chemotherapy for high-risk pathologic stage I non-small cell lung cancer. Ann Thorac Surg 113:1608–2161

    Article  PubMed  Google Scholar 

  20. Rizzo A, Cantale O, Mogavero A, Garetto L, Racca M, Venesio T et al (2023) Assessing the role of colonic and other anatomical sites uptake by [18F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors. Thorac Cancer 14:2473–2483

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Cvetkovic L, Régis C, Richard C, Derosa L, Leblond A, Malo J et al (2021) Physiologic colonic uptake of 18F-FDG on PET/CT is associated with clinical response and gut microbiome composition in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging 48:1550–1559

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Cathel Kerr, BSc, PhD, from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

Funding

This study has not been funded.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa, 920-0293, Japan

    Nozomu Motono, Takaki Mizoguchi, Masahito Ishikawa, Shun Iwai, Yoshihito Iijima & Hidetaka Uramoto

Authors
  1. Nozomu Motono
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takaki Mizoguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masahito Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shun Iwai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshihito Iijima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hidetaka Uramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NM performed the research, collected and analyzed the data and wrote the paper. TM, MI, SI, and YI contributed to sample collection. HU contributed to supervision of this study and revision of the manuscript. All authors have read and approved the manuscript, and ensure that this is the case.

Corresponding author

Correspondence to Nozomu Motono.

Ethics declarations

Competing interests

The authors declare that they have no competing interests.

Ethical Approval and Consent to Participate

The present study was conducted in accordance with the amended Declaration of Helsinki. The Institutional Review Boards of Kanazawa Medical University approved the protocol (approval number: I392), and written informed consent was obtained from all of the patients.

Consent to Publish

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Motono, N., Mizoguchi, T., Ishikawa, M. et al. Prognostic Impact of Cancer Inflammation Prognostic Index for Non-small Cell Lung Cancer. Lung 201, 603–610 (2023). https://doi.org/10.1007/s00408-023-00649-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-023-00649-z

Keywords

Search

Navigation